Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial

Jens Christian Laursen; Viktor Rotbain Curovic; Marjolein Y A M Kroonen; Niels Jongs; Emilie H Zobel; Tine W Hansen; Marie Frimodt-Møller; Gozewijn D Laverman; Adriaan Kooy; Frederik Persson; Hiddo J L Heerspink; Christian Stevns Hansen; Peter Rossing

doi:10.1111/dom.15180

Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial

Jens Christian Laursen, Viktor Rotbain Curovic, Marjolein Y A M Kroonen, Niels Jongs, Emilie H Zobel, Tine W Hansen, Marie Frimodt-Møller, Gozewijn D Laverman, Adriaan Kooy, Frederik Persson, Hiddo J L Heerspink, Christian Stevns Hansen, Peter Rossing

Steno Diabetes Center Copenhagen

5 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	Diabetes, Obesity and Metabolism
Vol/bind	25
Udgave nummer	10
Sider (fra-til)	3064-3067
Antal sider	4
ISSN	1462-8902
DOI	https://doi.org/10.1111/dom.15180
Status	Udgivet - okt. 2023

Adgang til dokumentet

10.1111/dom.15180

Andre filer og links

Link to publication in Scopus

Citationsformater

Laursen, J. C., Rotbain Curovic, V., Kroonen, M. Y. A. M., Jongs, N., Zobel, E. H., Hansen, T. W., Frimodt-Møller, M., Laverman, G. D., Kooy, A., Persson, F., Heerspink, H. J. L., Hansen, C. S., & Rossing, P. (2023). Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial. Diabetes, Obesity and Metabolism, 25(10), 3064-3067. https://doi.org/10.1111/dom.15180

Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial. / Laursen, Jens Christian; Rotbain Curovic, Viktor; Kroonen, Marjolein Y A M et al.
I: Diabetes, Obesity and Metabolism, Bind 25, Nr. 10, 10.2023, s. 3064-3067.

Publikation: Bidrag til tidsskrift › Letter › peer review

Laursen, JC, Rotbain Curovic, V, Kroonen, MYAM, Jongs, N, Zobel, EH, Hansen, TW , Frimodt-Møller, M, Laverman, GD, Kooy, A, Persson, F, Heerspink, HJL, Hansen, CS & Rossing, P 2023, 'Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial', Diabetes, Obesity and Metabolism, bind 25, nr. 10, s. 3064-3067. https://doi.org/10.1111/dom.15180

@article{4c8948cb65744367a26049b28938335f,

title = "Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial",

keywords = "SGLT2 inhibitor, clinical trial, diabetes complications, diabetic neuropathy, empagliflozin, linagliptin, Telmisartan/therapeutic use, Benzhydryl Compounds, Humans, Diabetic Neuropathies/drug therapy, Linagliptin/therapeutic use, Cross-Over Studies, Hypoglycemic Agents, Diabetes Mellitus, Type 1",

author = "Laursen, \{Jens Christian\} and \{Rotbain Curovic\}, Viktor and Kroonen, \{Marjolein Y A M\} and Niels Jongs and Zobel, \{Emilie H\} and Hansen, \{Tine W\} and Marie Frimodt-M{\o}ller and Laverman, \{Gozewijn D\} and Adriaan Kooy and Frederik Persson and Heerspink, \{Hiddo J L\} and Hansen, \{Christian Stevns\} and Peter Rossing",

year = "2023",

month = oct,

doi = "10.1111/dom.15180",

language = "English",

volume = "25",

pages = "3064--3067",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "10",

}

TY - JOUR

T1 - Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes

T2 - An exploratory, randomized, open-label, crossover trial

AU - Laursen, Jens Christian

AU - Rotbain Curovic, Viktor

AU - Kroonen, Marjolein Y A M

AU - Jongs, Niels

AU - Zobel, Emilie H

AU - Hansen, Tine W

AU - Frimodt-Møller, Marie

AU - Laverman, Gozewijn D

AU - Kooy, Adriaan

AU - Persson, Frederik

AU - Heerspink, Hiddo J L

AU - Hansen, Christian Stevns

AU - Rossing, Peter

PY - 2023/10

Y1 - 2023/10

KW - SGLT2 inhibitor

KW - clinical trial

KW - diabetes complications

KW - diabetic neuropathy

KW - empagliflozin

KW - linagliptin

KW - Telmisartan/therapeutic use

KW - Benzhydryl Compounds

KW - Humans

KW - Diabetic Neuropathies/drug therapy

KW - Linagliptin/therapeutic use

KW - Cross-Over Studies

KW - Hypoglycemic Agents

KW - Diabetes Mellitus, Type 1

UR - https://www.scopus.com/pages/publications/85164196800

U2 - 10.1111/dom.15180

DO - 10.1111/dom.15180

M3 - Letter

C2 - 37385968

SN - 1462-8902

VL - 25

SP - 3064

EP - 3067

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 10

ER -